A bronchial disease that is characterized by chronic inflammation and narrowing of the airways, which is caused by a combination of environmental and genetic factors resulting in recurring periods of ...
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 5, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 5, 2026
Helpful links for rare disease information and support
Questions that may be helpful when speaking with your healthcare team
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 5, 2026
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning asthma
Updated Feb 5, 2026
Generate Biomedicines, an AI-driven biotech startup, has filed for an IPO after raising over $800 million for its drug discovery efforts. The company is developing a potential competitor to Tezspire for asthma treatment and plans to advance another drug into clinical trials in early 2024.
Eli Lilly reported $19.3 billion in revenue for Q4 and is expanding its GLP-1 franchise into immunology and inflammation. Ongoing trials target asthma, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Generate Biomedicines has filed for a $100 million IPO to advance its AI-driven drug discovery platform focused on severe asthma therapies. This Phase 3 biotech aims to leverage its technology to enhance treatment options in this area.
A new CDC report reveals that asthma diagnoses in the U.S. increased by 4.3 million from 2001 to 2009, highlighting a growing public health concern. This trend underscores the need for enhanced awareness and advocacy efforts in managing asthma.
CDC will hold a media briefing to discuss new Vital Signs reports on asthma prevalence and self-management education in the U.S. from 2001 to 2009. This briefing aims to raise awareness about asthma and its characteristics.